# Sparsentan in Posttransplant Immunoglobulin A Nephropathy or Focal Segmental Glomerulosclerosis

> **NCT07219121** · PHASE4 · RECRUITING · sponsor: **Travere Therapeutics, Inc.** · enrollment: 20 (estimated)

## Conditions studied

- Proteinuria
- Immunoglobulin A (IgA) Nephropathy
- Focal Segmental Glomerulosclerosis
- Kidney Transplant

## Interventions

- **DRUG:** Sparsentan

## Key facts

- **NCT ID:** NCT07219121
- **Lead sponsor:** Travere Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-07
- **Primary completion:** 2027-03
- **Final completion:** 2027-05
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07219121

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07219121, "Sparsentan in Posttransplant Immunoglobulin A Nephropathy or Focal Segmental Glomerulosclerosis". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT07219121. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*